Allergan plc announced earnings results for the fourth quarter ended December 31, 2018. For the fourth quarter, the company announced sales was USD 4,079.7 million compared to USD 4,326.1 million a year ago. Operating loss was USD 5,384.1 million compared to USD 90.5 million a year ago. Net loss was USD 4,299.9 million compared to net income of USD 3,121.3 million a year ago. Basic loss per share from continuing operations was USD 12.83 compared to basic earnings per share from continuing operations of USD 10.37 a year ago. Basic loss per share was USD 12.83 compared to basic earnings per share of USD 9.21 a year ago. Diluted loss per share from continuing operations was USD 12.83 compared to diluted earnings per share from continuing operations of USD 9.97 a year ago. Diluted loss per share was USD 12.83 compared to diluted earnings per share of USD 8.88 a year ago. For the full year, sales was USD 15,787.4 million compared to USD 15,940.7 million a year ago. Operating loss was USD 6,247.6 million compared to USD 5,921.2 million a year ago. Net loss was USD 5,096.4 million compared to USD 4,125.5 million a year ago. Basic loss per share from continuing operations was USD 15.26 compared to USD 11.99 a year ago. Basic loss per share was USD 15.26 compared to USD 13.19 a year ago.